X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1080) 1080
male (841) 841
sitagliptin phosphate (838) 838
diabetes mellitus, type 2 - drug therapy (813) 813
sitagliptin (757) 757
female (640) 640
middle aged (569) 569
hypoglycemic agents - therapeutic use (538) 538
type 2 diabetes (464) 464
endocrinology & metabolism (440) 440
pyrazines - therapeutic use (436) 436
triazoles - therapeutic use (435) 435
diabetes (428) 428
aged (419) 419
dipeptidyl-peptidase iv inhibitors - therapeutic use (387) 387
animals (362) 362
treatment outcome (326) 326
adult (298) 298
diabetes mellitus, type 2 - blood (292) 292
sitagliptin phosphate - therapeutic use (291) 291
metformin (278) 278
hypoglycemic agents (268) 268
pharmacology & pharmacy (263) 263
drug therapy, combination (252) 252
dipeptidyl peptidase-4 inhibitor (251) 251
glucose (250) 250
glucagon-like peptide-1 (245) 245
hypoglycemic agents - adverse effects (242) 242
dipeptidyl-peptidase iv inhibitors - pharmacology (239) 239
hypoglycemic agents - administration & dosage (235) 235
glycemic control (234) 234
pyrazines - pharmacology (229) 229
blood glucose - metabolism (227) 227
triazoles - pharmacology (227) 227
diabetes mellitus (214) 214
double-blind (208) 208
insulin (207) 207
blood glucose - drug effects (206) 206
triazoles - administration & dosage (203) 203
pyrazines - administration & dosage (202) 202
care and treatment (188) 188
double-blind method (185) 185
rats (185) 185
pyrazines - adverse effects (184) 184
safety (184) 184
metformin - therapeutic use (183) 183
hypoglycemic agents - pharmacology (182) 182
triazoles - adverse effects (182) 182
efficacy (178) 178
glycated hemoglobin a - metabolism (177) 177
adamantane - analogs & derivatives (162) 162
analysis (161) 161
dipeptidyl-peptidase iv inhibitors - adverse effects (159) 159
sitagliptin phosphate - pharmacology (154) 154
mice (150) 150
dipeptidyl-peptidase iv inhibitors - administration & dosage (138) 138
medicine, general & internal (135) 135
diabetes mellitus, type 2 - complications (131) 131
research (130) 130
dipeptidyl peptidase 4 - metabolism (128) 128
diabetes therapy (124) 124
sitagliptin phosphate - adverse effects (121) 121
vildagliptin (119) 119
sitagliptin phosphate - administration & dosage (116) 116
drug therapy (114) 114
mellitus (113) 113
glucagon (112) 112
dextrose (111) 111
hyperglycemia (111) 111
therapy (111) 111
dosage and administration (110) 110
glycated hemoglobin a - analysis (110) 110
adamantane - therapeutic use (108) 108
beta-cell function (108) 108
internal medicine (108) 108
clinical trials (105) 105
insulin resistance (105) 105
metformin - administration & dosage (105) 105
medicine, research & experimental (101) 101
glp-1 (100) 100
risk factors (99) 99
peptides - therapeutic use (98) 98
dpp-4 inhibitor (97) 97
liraglutide (96) 96
peptidase (95) 95
monotherapy (94) 94
venoms - therapeutic use (94) 94
inflammation (92) 92
diabetes mellitus, type 2 - metabolism (90) 90
dose-response relationship, drug (90) 90
hypoglycemia (90) 90
cardiac & cardiovascular systems (89) 89
oxidative stress (88) 88
type 2 diabetes mellitus (88) 88
dipeptidyl peptidase-4 inhibitors (87) 87
body weight (86) 86
dipeptidyl-peptidase iv inhibitors (86) 86
peptides (86) 86
time factors (85) 85
type-2 diabetes-mellitus (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1473) 1473
German (25) 25
Japanese (12) 12
French (11) 11
Chinese (10) 10
Spanish (9) 9
Portuguese (8) 8
Hungarian (6) 6
Czech (3) 3
Dutch (3) 3
Russian (3) 3
Korean (2) 2
Swedish (2) 2
Italian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecules (Basel, Switzerland), ISSN 1420-3049, 2018, Volume 23, Issue 6, p. 1440
Journal Article
Journal Article
Scientia pharmaceutica, ISSN 0036-8709, 2012, Volume 80, Issue 1, pp. 139 - 152
...) method for the simultaneous determination of Sitagliptin phosphate monohydrate and Metformin hydrochloride in pharmaceutical dosage forms... 
Validation | UPLC | Metformin hydrochloride | Simultaneous | Sitagliptin phosphate monohydrate | Chromatography | Stability-indicating method
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TO-TARGET TRIAL | BEGIN | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Complications | Research
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
Chemistry – An Asian Journal, ISSN 1861-4728, 05/2020, Volume 15, Issue 10, pp. 1605 - 1608
An alternate formal synthesis of Sitagliptin phosphate is disclosed from 2,4,5‐trifluorobenzadehyde in 8 linear steps with an overall yield of 31%. The chiral β... 
Sitagliptin phosphate | Asymmetric Hydrogenation | Hoffmann rearrangement | ASYMMETRIC-SYNTHESIS | HYDROGENATION | C2-SYMMETRICAL BIS(PHOSPHOLANES) | CHEMISTRY, MULTIDISCIPLINARY | LIGANDS | AMINES | HOFMANN REARRANGEMENT | IV INHIBITOR | GENERATION | EFFICIENT | DERIVATIVES
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 378 - 388
Aims To assess the safety and efficacy of monotherapy with once‐weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes... 
GLP‐1 | sitagliptin | type 2 diabetes | GLP-1 | METFORMIN | ADD-ON | AMERICAN ASSOCIATION | HUMAN GLP-1 ANALOG | EXENATIDE | PHASE 3A | OPEN-LABEL | CLINICAL ENDOCRINOLOGISTS | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | ACUTE-PANCREATITIS | Glycated Hemoglobin A - analysis | Follow-Up Studies | Nausea - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diarrhea - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glucagon-Like Peptides - administration & dosage | Humans | Nausea - physiopathology | Patient Dropouts | Weight Loss - drug effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Nausea - therapy | Injections, Subcutaneous | Hypoglycemia - chemically induced | Severity of Illness Index | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Drug Administration Schedule | Administration, Oral | Japan | Constipation - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Constipation - chemically induced | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diarrhea - therapy | Constipation - therapy | Incretins - adverse effects | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Diabetes mellitus | Body weight | Hemoglobin | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Original
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 09/2018, Volume 2018, Issue 9, p. CD011798
Background Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co‐exist. Glucometabolic changes and concurrent dialysis... 
Kidney disease | Glomerular diseases | Renal Insufficiency, Chronic | Diabetic Nephropathies | Pharmacological interventions | Glucagon‐Like Peptide 1 | Sodium‐Glucose Transporter 2 | Glipizide | Chronic kidney disease | Dipeptidyl‐Peptidase IV Inhibitors | Diabetes Mellitus | Insulin | Cause of Death | Randomized Controlled Trials as Topic | Hypoglycemic Agents | Sodium‐Glucose Transporter 2 Inhibitors | Glycated Hemoglobin A | Child health | Glomerular disease | Sitagliptin Phosphate | Medicine General & Introductory Medical Sciences | Thiazolidinediones | Diabetic kidney disease | GLOMERULAR-FILTRATION-RATE | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INTENSIVE GLYCEMIC CONTROL | CONTROL CARDIOVASCULAR RISK | COTRANSPORTER 2 INHIBITOR | QUALITY-OF-LIFE | CORONARY-ARTERY-DISEASE | LONG-TERM EFFICACY | SEVERE RENAL IMPAIRMENT | BASE-LINE CHARACTERISTICS | Diabetes Mellitus - blood | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Glipizide - adverse effects | Glycated Hemoglobin A - drug effects | Diabetic Nephropathies - drug therapy | Glipizide - therapeutic use | Diabetic Nephropathies - blood | Renal Insufficiency, Chronic - drug therapy | Thiazolidinediones - therapeutic use | Glucagon-Like Peptide 1 - agonists | Renal Insufficiency, Chronic - mortality | Diabetes Mellitus - mortality | Hypoglycemic Agents - therapeutic use | Diabetes Mellitus - drug therapy | Sodium-Glucose Transporter 2 Inhibitors | Sodium-Glucose Transporter 2 | Diabetic Nephropathies - mortality | Renal Insufficiency, Chronic - blood | Sitagliptin Phosphate - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Sitagliptin Phosphate - adverse effects
Journal Article